Liposomal doxorubicin and estramustine phosphate: a phase II study in taxane resistant, hormone refractory advanced prostate cancer

Trial Profile

Liposomal doxorubicin and estramustine phosphate: a phase II study in taxane resistant, hormone refractory advanced prostate cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 14 Nov 2006

At a glance

  • Drugs Doxorubicin liposomal; Estramustine
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 14 Nov 2006 Status change
    • 03 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top